Posted in | News | Business

Linde Gases Shipped First Container from the Helium II Facility Operated by Ras Gas

Linde Gases, a division of The Linde Group, has today shipped the first container from its newest helium source, Helium II, operated by Ras Gas at the Ras Laffan Industrial City in Qatar. Linde has secured long term rights to 30 percent of the output from this latest and largest helium source in the world, further demonstrating its commitment to ensure a steady supply of one of the world's rarest and most sought-after gases.

Helium is critical to the manufacture and operation of MRI scanners as well as the manufacture of semiconductors, LCD screens and fibre optic cable. As it can only be economically produced from helium-rich natural gas sources, there are only a limited number of helium production facilities around the world.

"Due to its unique properties, relative scarcity and global supply chain, helium is one of only a few industrial gases with a truly global market," said Steve Penn, Global Head of Merchant and Packaged Gases, Linde Gases Division. "We have therefore strengthened our supply base in Qatar building on our long-term commitment with the first plant there in 2005. Helium II further reinforces Linde's position as having the most diverse helium sourcing portfolio in the industry, including sources in Algeria, Australia and the US."

Hamad Rashid Al Mohannadi, RasGas Chief Executive Officer and Vice Chairman of Qatar Petroleum (QP) said, "The Helium II plant, which broke ground in May 2010, is the second helium project to be built in Qatar, and we are very pleased to report that in over 5 million man hours worked to complete this project, we have maintained a lost time incident rate (LTIR) of zero. Achieving such a remarkable milestone is a clear testimony to RasGas' commitment to creating and maintaining a safe work environment in a complex construction project that involved thousands of contractors and employees."

Linde is investing over EUR 35 million in new containers to supply the additional helium from Helium II and its expanded source in Skikda, Algeria. Linde is also investing to expand its transfill and container staging facility in the Jebel Ali Free Zone in Dubai to accommodate the growth.

Over the past 10 years, Linde has invested heavily in new source development and long term commitments with third party producers. Along with Skikda, output from both Qatar plants and its own facility in Darwin, Australia, Linde will have brought to market more helium than any other company. Additionally, in December 2012, Russian company Gazprom Export and Linde signed a Memorandum of Understanding (MOU) stipulating cooperation to implement new helium production projects concurrently with the development of the Eastern Siberia gas fields.

Helium II will support Linde's global growth agenda, particularly in Asia.

Source: http://www.linde.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Linde plc. (2019, February 09). Linde Gases Shipped First Container from the Helium II Facility Operated by Ras Gas. AZoM. Retrieved on April 19, 2024 from https://www.azom.com/news.aspx?newsID=37467.

  • MLA

    Linde plc. "Linde Gases Shipped First Container from the Helium II Facility Operated by Ras Gas". AZoM. 19 April 2024. <https://www.azom.com/news.aspx?newsID=37467>.

  • Chicago

    Linde plc. "Linde Gases Shipped First Container from the Helium II Facility Operated by Ras Gas". AZoM. https://www.azom.com/news.aspx?newsID=37467. (accessed April 19, 2024).

  • Harvard

    Linde plc. 2019. Linde Gases Shipped First Container from the Helium II Facility Operated by Ras Gas. AZoM, viewed 19 April 2024, https://www.azom.com/news.aspx?newsID=37467.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.